CSF3 and acute promyelocytic leukemia: Acute myeloid leukemia (AML) is a heterogenous malignant clonal disease characterized by the accumulation of undifferentiated myeloid blasts, which predisposes patients, especially those with APL-type AML, to overcome impaired differentiation via differentiation-inducing agents, such as granulocyte-colony stimulating factor (GCSF) or ATRA, in addition to conventional chemotherapy [21, 22].